JP2022515820A5 - - Google Patents

Info

Publication number
JP2022515820A5
JP2022515820A5 JP2021537704A JP2021537704A JP2022515820A5 JP 2022515820 A5 JP2022515820 A5 JP 2022515820A5 JP 2021537704 A JP2021537704 A JP 2021537704A JP 2021537704 A JP2021537704 A JP 2021537704A JP 2022515820 A5 JP2022515820 A5 JP 2022515820A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
pharmaceutical composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021537704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515820A (ja
JP7507160B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/RU2019/050257 external-priority patent/WO2020139171A1/ru
Publication of JP2022515820A publication Critical patent/JP2022515820A/ja
Publication of JP2022515820A5 publication Critical patent/JP2022515820A5/ja
Application granted granted Critical
Publication of JP7507160B2 publication Critical patent/JP7507160B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021537704A 2018-12-25 2019-12-24 ヒトtrbv9に特異的に結合するモノクローナル抗体 Active JP7507160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2018146029A RU2711871C3 (ru) 2018-12-25 Моноклональные антитела, которые специфически связываются с участком бета цепи семейства TRBV-9 Т-клеточного рецептора человека, и способы их применения
RU2018146029 2018-12-25
PCT/RU2019/050257 WO2020139171A1 (ru) 2018-12-25 2019-12-24 Моноклональные антитела, специфически связывающиеся с trbv-9 человека

Publications (3)

Publication Number Publication Date
JP2022515820A JP2022515820A (ja) 2022-02-22
JP2022515820A5 true JP2022515820A5 (cg-RX-API-DMAC7.html) 2023-01-10
JP7507160B2 JP7507160B2 (ja) 2024-06-27

Family

ID=69184146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537704A Active JP7507160B2 (ja) 2018-12-25 2019-12-24 ヒトtrbv9に特異的に結合するモノクローナル抗体

Country Status (26)

Country Link
US (1) US12297269B2 (cg-RX-API-DMAC7.html)
EP (2) EP4721817A2 (cg-RX-API-DMAC7.html)
JP (1) JP7507160B2 (cg-RX-API-DMAC7.html)
KR (1) KR102974826B1 (cg-RX-API-DMAC7.html)
CN (1) CN113692412B (cg-RX-API-DMAC7.html)
AR (1) AR117735A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021012550A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124800A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001704A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021008204A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210353A (cg-RX-API-DMAC7.html)
EA (1) EA202100199A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21046332A (cg-RX-API-DMAC7.html)
IL (1) IL284367A (cg-RX-API-DMAC7.html)
JO (1) JOP20210168B1 (cg-RX-API-DMAC7.html)
MA (1) MA53688B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021007718A (cg-RX-API-DMAC7.html)
MY (1) MY206214A (cg-RX-API-DMAC7.html)
PE (1) PE20211792A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551535A1 (cg-RX-API-DMAC7.html)
RS (1) RS68101B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106974SA (cg-RX-API-DMAC7.html)
SM (1) SMT202600227T1 (cg-RX-API-DMAC7.html)
TW (1) TWI914298B (cg-RX-API-DMAC7.html)
WO (1) WO2020139171A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104356B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TW202417487A (zh) * 2022-08-18 2024-05-01 俄羅斯聯邦商拜奧卡德聯合股份公司 治療在t細胞受體內帶有trbv9節段的t淋巴細胞所介導的疾病或病症之方法
KR20260085152A (ko) * 2023-10-04 2026-06-08 조인트 스탁 컴퍼니 "바이오케드" 인간 tcr 도메인의 trbv5-1 세그먼트에 결합하는 항체

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
CA2765949C (en) * 2009-06-25 2016-03-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
TW201208701A (en) 2010-07-12 2012-03-01 Daiichi Sankyo Co Ltd Anti-EPHA2 antibodies and uses thereof
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
DK2991683T3 (da) * 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
EP3202784A1 (en) * 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
JP6989138B2 (ja) 2016-06-17 2022-01-05 メディジーン イミュノテラピーズ ゲーエムベーハー T細胞受容体及びその使用
AU2017356322B2 (en) * 2016-11-14 2023-09-21 Fred Hutchinson Cancer Center High affinity merkel cell polyomavirus T antigen-specific TCRs and uses thereof
JP7162607B2 (ja) * 2017-02-27 2022-10-28 中外製薬株式会社 抗hla-dq2.5/8抗体およびセリアック病の治療のためのその使用
CN107502671B (zh) * 2017-10-12 2020-05-05 中国医学科学院肿瘤医院 利用trbv家族成员预测曲妥珠单抗新辅助治疗乳腺癌患者疗效试剂盒及其应用
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения

Similar Documents

Publication Publication Date Title
JP2022532274A5 (cg-RX-API-DMAC7.html)
EP3645742B1 (en) Anti-ror1 antibodies and methods of making and using thereof
RU2504553C2 (ru) Антитела к her
JP2021058215A (ja) Ror1癌の治療および転移の阻害に使用するための抗体およびワクチン
RU2451689C2 (ru) Новые антипролиферативные антитела
Li et al. CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells
CN112513089A (zh) 抗cd73抗体、其抗原结合片段及应用
JP2020532965A5 (cg-RX-API-DMAC7.html)
RU2013153592A (ru) Анти-mif антитела
RU2013102225A (ru) АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2016520520A5 (cg-RX-API-DMAC7.html)
JP2014503189A5 (cg-RX-API-DMAC7.html)
HRP20240102T1 (hr) Monoklonsko protutijelo koje antagonizira i inhibira vezanje između humanog pd-1 antigena i njegovog liganda, postupak njegove priprave i primjena
JP2013520984A5 (cg-RX-API-DMAC7.html)
US20250313630A1 (en) Ph-selective anti-cd3 antibodies and use of the same
SA515360248B1 (ar) أجسام مضادة cd26 واستخداماتها
AU2019301336B2 (en) Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
WO2017186182A1 (en) Humanized anti-basigin antibodies and the use thereof
JP2022516071A5 (cg-RX-API-DMAC7.html)
JP2018502068A5 (cg-RX-API-DMAC7.html)
JP2009524428A5 (cg-RX-API-DMAC7.html)
CN114805570B (zh) 一种抗人ace2单克隆抗体及其应用
CN114149498B (zh) 抗人emc10的单克隆抗体在防治2型糖尿病中的应用
WO2014139425A1 (zh) 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
IL277899B1 (en) Methods and compositions for treating yellow fever